This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Tobacco  • Cardiovascular System  • Statistics and Research Methods  • Prognosis/ Outcomes  • Cardiovascular Disease/ Myocardial Infarction  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: Dr Ho and colleagues¹ reported that concomitant use of clopidogrel and a proton pump inhibitor (PPI) after discharge from hospital for acute coronary syndrome (ACS) was associated with an increased risk of rehospitalization for ACS, compared with use of clopidogrel without PPI. Based on their observations, the authors concluded that, although causality cannot be claimed, PPIs should be used based on clear clinical indications rather than prophylactic prescription. Reconsideration of prophylactic prescription of PPIs in patients with ACS has been ongoing.² However, the recent American College of Cardiology Foundation/American College of Gastroenterology/American Heart Association (ACCF/ACG/AHA) guidelines still recommend using PPIs for aspirin users with a history of myocardial infarction, many of whom are also using clopidogrel.³

The study by Ho et al found differences only in hospitalization for ACS, not in mortality. We therefore suggest that the authors compare the incidences of gastrointestinal hemorrhage and related hospitalization . . . [Full Text of this Article]

Young Kwang Chae, MD, MPH, MBA
youngkwang.chae@gmail.com

Jongoh Kim, MD
Department of Medicine
Albert Einstein Medical Center
Philadelphia, Pennsylvania

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?